Your session is about to expire
← Back to Search
Clipping vs Coiling for Brain Aneurysm (MCAAT Trial)
N/A
Recruiting
Led By Tim Darsaut
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients at least 18 years of age
In the case of SAH, WFNS grade 4 or less
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years or until death, whichever came first
Awards & highlights
MCAAT Trial Summary
This trial is testing whether clipping or coiling is better for treating intracranial aneurysms located on the middle cerebral artery.
Who is the study for?
This trial is for adults with a brain aneurysm located on the middle cerebral artery, which can be treated by surgery or endovascular methods. It includes those with recent or older ruptures (over 30 days old) who are in stable condition (WFNS grade 4 or less). People allergic to contrast material, unable to consent, with AVM-related aneurysms, or severe ruptures (WFNS grade 5) cannot join.Check my eligibility
What is being tested?
The study compares surgical clipping versus endovascular treatment for MCA aneurysms. Surgical clipping might be preferred due to easier access and control during rupture. Endovascular options include stents and flow disruptors but face challenges like wide necks of the aneurysm.See study design
What are the potential side effects?
Surgical management may lead to risks such as infection, bleeding, stroke-like symptoms due to vessel damage. Endovascular treatments could cause similar issues along with specific complications from devices used like stent misplacement or reaction.
MCAAT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
My SAH condition is not the most severe.
Select...
I have at least one aneurysm in my brain's MCA vessel, whether it has burst or not.
MCAAT Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years or until death, whichever came first
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years or until death, whichever came first
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Treatment Success
Secondary outcome measures
Failure of aneurysm occlusion using the intended treatment modality
The occurrence of an intracranial hemorrhage following treatment
Other outcome measures
Overall morbidity
Perinatal death
The presence of a residual aneurysm at one year (12 ± 2 months)
MCAAT Trial Design
2Treatment groups
Active Control
Group I: Surgical managementActive Control1 Intervention
Group II: Endovascular managementActive Control1 Intervention
Find a Location
Who is running the clinical trial?
University of AlbertaLead Sponsor
888 Previous Clinical Trials
384,558 Total Patients Enrolled
Tim DarsautPrincipal InvestigatorUniversity of Alberta Faculty of Medicine and Dentistry
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am unable to give consent myself.I have an aneurysm linked to my AVM condition.I am 18 years old or older.I cannot receive contrast material due to severe allergies or reactions.I have a severe brain aneurysm that has burst.My SAH condition is not the most severe.I have at least one aneurysm in my brain's MCA vessel, whether it has burst or not.My team considers me fit for surgery or a less invasive procedure for my aneurysm.
Research Study Groups:
This trial has the following groups:- Group 1: Surgical management
- Group 2: Endovascular management
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are any new participants able to enter this medical experiment?
"Clinicaltrials.gov verifies that this research is actively recruiting as of July 6th 2022, since it was first published on May 15th 2022."
Answered by AI
How many individuals are currently receiving treatment through this research endeavor?
"Yes, the clinicaltrials.gov website verifies that recruitment is still open for this trial, which was posted on May 15th 2022 and most recently updated July 6th 2022. The study seeks to enrol 400 participants from a single site."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger